ライフサイエンスコーパス: pulmonary hypertension

1 odeling in a rat model of angio-obliterative pulmonary hypertension.

2 tor of CLIC4 and a new therapeutic target in pulmonary hypertension.

3 or hormone metabolism to the development of pulmonary hypertension.

4 isk associated with oversized prostheses and pulmonary hypertension.

5 ladaptation and failure determine outcome in pulmonary hypertension.

6 various pulmonary vascular diseases, such as pulmonary hypertension.

7 RV pressure-volume loops in 42 patients with pulmonary hypertension.

8 tic accuracy in patients suspected of having pulmonary hypertension.

9 ntribution to right ventricle dysfunction in pulmonary hypertension.

10 llular oxygen homeostasis, angiogenesis, and pulmonary hypertension.

11 d ejection fraction and mostly consequent to pulmonary hypertension.

12 of beta-agonists in HFpEF and other forms of pulmonary hypertension.

13 pressure <=15 mm Hg without another cause of pulmonary hypertension.

14 ater than 32 mm Hg predicted the presence of pulmonary hypertension.

15 power to predict whether or not patients had pulmonary hypertension.

16 ate pulmonary artery pressure and to predict pulmonary hypertension.

17 ssible development of chronic thromboembolic pulmonary hypertension.

18 tial as new drug targets in the treatment of pulmonary hypertension.

19 rom the Dutch National Network for Pediatric Pulmonary Hypertension.

20 y introduced as a novel treatment option for pulmonary hypertension.

21 for understanding the changes that occur in pulmonary hypertension.

22 f subsets of patients with heart failure and pulmonary hypertension.

23 ent knowledge on the use of beta-blockers in pulmonary hypertension.

24 nderlies increased vascular contractility in pulmonary hypertension.

25 ter to measure in follow-up of patients with pulmonary hypertension.

26 fy Cpc-PH patients as isolated postcapillary pulmonary hypertension.

27 s to support the right ventricle function in pulmonary hypertension.

28 ute to the increased tone that characterizes pulmonary hypertension.

29 ry endarterectomy for chronic thromboembolic pulmonary hypertension.

30 mpared with nonsevere chronic thromboembolic pulmonary hypertension.

31 erved ejection fraction and exercise-induced pulmonary hypertension.

32 d therapies targeting the right ventricle in pulmonary hypertension.

33 onist is among the most effective agents for pulmonary hypertension.

34 ly protected against chronic hypoxia-induced pulmonary hypertension.

35 robust, chronic inflammatory mouse model of pulmonary hypertension.

36 g stress echocardiography, and patients with pulmonary hypertension.

37 y important roles in the pulmonary artery in pulmonary hypertension.

38 d to elevated LV end-diastolic pressures and pulmonary hypertension.

39 isk factors in patients with newly diagnosed pulmonary hypertension.

40 some of these treatments improve SCD-related pulmonary hypertension.

41 rs) underwent PEA for chronic thromboembolic pulmonary hypertension.

42 get for therapy in selected HF patients with pulmonary hypertension.

43 pg/mL; 217 of 3223 cohort members (6.7%) had pulmonary hypertension.

44 ients with PE develop chronic thromboembolic pulmonary hypertension.

45 ulmonary vasoconstriction and progression of pulmonary hypertension.

46 transcription factor in the pathogenesis of pulmonary hypertension.

47 outcome after PEA in chronic thromboembolic pulmonary hypertension.

48 egenerate pulmonary microvessels and reverse pulmonary hypertension.

49 129)Xe MRI to the monocrotaline rat model of pulmonary hypertension.

50 munity are limited and largely restricted to pulmonary hypertension.

51 hmic drug for the treatment of patients with pulmonary hypertension.

52 es pulmonary artery pressure in animals with pulmonary hypertension.

53 atients with operable chronic thromboembolic pulmonary hypertension.

54 sfunction and poor survival in patients with pulmonary hypertension.

55 f miR410 in the pathogenesis of experimental pulmonary hypertension.

56 iving mechanical ventilation and may predict pulmonary hypertension.

57 ced right ventricular failure in established pulmonary hypertension.

58 on, and risk stratification of patients with pulmonary hypertension.

59 ng they could develop chronic thromboembolic pulmonary hypertension.

60 8.5 Woods units) were consistent with severe pulmonary hypertension.

61 o detect pending RV failure in patients with pulmonary hypertension.

62 isruption may be an important contributor to pulmonary hypertension.

63 r than traditional HRV parameters to predict pulmonary hypertension.

64 time less than 40 ms respectively predicted pulmonary hypertension 100% of the time and had a 100% n

65 We prospectively analyzed 57 patients with pulmonary hypertension (31 with pulmonary arterial hyper

66 PE + SU rats exhibited sustained pulmonary hypertension (62 +/- 13 and 53 +/- 14 mmHg at

67 Such models of preclinical pulmonary hypertension, a disease of the pulmonary vascu

68 ology, and emerging clinical perspectives on pulmonary hypertension across the broad spectrum of hear

69 Pulmonary hypertension affects approximately 10% of adul

70 erve lung structure and function and prevent pulmonary hypertension after intrauterine inflammation i

71 ticular, our findings raise the suspicion of pulmonary hypertension after IUGR.

72 inoperable CTEPH or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy (P

73 medical subject headings and text words for pulmonary hypertension and health disparities.

74 gher risk of dying of chronic thromboembolic pulmonary hypertension and identifies a level of residua

75 nic obstructive pulmonary disease-associated pulmonary hypertension and in rats with PAH, Kv11.1 chan

76 nic obstructive pulmonary disease-associated pulmonary hypertension and in the lungs of rats with pul

77 domised, placebo-controlled study done at 65 pulmonary hypertension and interstitial lung disease cen

78 ding the classic models (ie, hypoxia-induced pulmonary hypertension and monocrotaline lung injury mod

79 ignaling could be useful in the treatment of pulmonary hypertension and other vascular disease.

80 In contrast, chronic hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling

81 Pulmonary hypertension and pulmonary vascular remodeling

82 Patients with pulmonary hypertension and right heart failure have a hi

83 f PH and may be appropriate for treatment of pulmonary hypertension and RV dysfunction.

84 oke, and other CVD manifestations, including pulmonary hypertension and sudden cardiac death, are sig

85 ertension and 26 with chronic thromboembolic pulmonary hypertension) and compared them to 57 age- and

86 hemic heart disease, valvular heart disease, pulmonary hypertension, and congenital heart disease.

87 eders" were correlated with cardiac failure, pulmonary hypertension, and encephalomalacia at birth.

88 ease, manifested as pronounced leukocytosis, pulmonary hypertension, and even death.

89 at the horizon as arrhythmias, endocarditis, pulmonary hypertension, and heart failure, and the need

90 increased risk for development of late-onset pulmonary hypertension, and may be particularly suscepti

91 AI was also associated with stroke, pulmonary hypertension, and priapism, and cf-PWV was ass

92 ET(A)R antagonist approved for treatment of pulmonary hypertension, and re-expressing the ET(B)R gen

93 ients with compromised right heart function, pulmonary hypertension, and severe acute hypoxemic respi

94 in gallstones, extramedullary hematopoiesis, pulmonary hypertension, and thrombosis, are related to t

95 tricular failure in those with postcapillary pulmonary hypertension; and hydroxyurea or transfusions

96 helial cells specifically resulted in severe pulmonary hypertension ( approximately 118% increase in

97 ctors, such as severity of liver disease and pulmonary hypertension, are not included in the exceptio

98 ides an update on venous thromboembolism and pulmonary hypertension associated with cancer therapies.

99 There are no approved treatments for pulmonary hypertension associated with idiopathic inters

100 , we successfully detected four well-defined pulmonary hypertension-associated biomarkers, namely, fi

101 was common and independently associated with pulmonary hypertension, atrial fibrillation, and more se

102 rtension, and in patients with postcapillary pulmonary hypertension because of left heart disease.

103 or of outcomes in patients with precapillary pulmonary hypertension because of pulmonary arterial hyp

104 F, grade III or IV aortic regurgitation, and pulmonary hypertension both at discharge from the index

105 phy, helps identify SCD patients at risk for pulmonary hypertension, but definitive diagnosis require

106 n healthy volunteers and three patients with pulmonary hypertension by using a stimulated echo sequen

107 , WHO functional classes II-IV, precapillary pulmonary hypertension confirmed by right heart catheter

108 Long-Term PAH Disease Management score, the Pulmonary Hypertension Connection equation, and the Mayo

109 dities, including gastro-oesophageal reflux, pulmonary hypertension, coronary artery disease, and mal

110 d mechanisms of right ventricular failure in pulmonary hypertension could be predicted by using super

111 ostcapillary and combined pre-/postcapillary pulmonary hypertension (Cpc-PH) in left heart disease (P

112 atients with residual chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary endartere

113 microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hy

114 Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by defec

115 Chronic thromboembolic pulmonary hypertension (CTEPH) is the result of pulmonar

116 Treatment options for chronic thromboembolic pulmonary hypertension (CTEPH) that is not amenable to t

117 d in 34 patients with chronic thromboembolic pulmonary hypertension (CTEPH) undergoing invasive treat

118 Chronic thromboembolic pulmonary hypertension (CTEPH) was confirmed in 4 (2.1%)

119 hysiological basis of chronic thromboembolic pulmonary hypertension (CTEPH) will be accelerated by an

120 ical surveillance for chronic thromboembolic pulmonary hypertension (CTEPH), with ventilation-perfusi

121 Cross-sectional analysis: presence of pulmonary hypertension (defined as an elevated pulmonary

122 Pulmonary hypoplasia (PH) and pulmonary hypertension determine mortality and morbidity

123 a contributor to preoperative heart failure, pulmonary hypertension did not significantly influence c

124 sing system to detect multiple biomarkers of pulmonary hypertension diseases in a single device.

125 For patients with pulmonary hypertension due to left-sided heart disease o

126 Although some infants develop early onset pulmonary hypertension, due to the unique adaptive capab

127 ulmonary artery in subjects with and without pulmonary hypertension during spontaneous respiration an

128 Pulmonary comorbidities include pulmonary hypertension, emphysema, and lung cancer, whil

129 ical and prognostic implications of exercise pulmonary hypertension (exPH) among broader samples rema

130 tachycardia, mechanical ventilation, sepsis, pulmonary hypertension, extracorporeal membrane oxygenat

131 ls, and TLR3(-/-) mice exhibited more severe pulmonary hypertension following exposure to chronic hyp

132 and Blood Institute initiative to reclassify pulmonary hypertension groups based on clustered phenoty

133 beyond the traditional 5 World Symposium on Pulmonary Hypertension groups.

134 d severe or nonsevere chronic thromboembolic pulmonary hypertension (> 900 or </= 900 dynes.s/cm, res

135 The patients with pulmonary hypertension had significantly lower mean RR,

136 In conclusion, the patients with pulmonary hypertension had worse heart rhythm complexity

137 Interest in left-sided pulmonary hypertension has increased remarkably in recen

138 ation between plasma endothelin-1 levels and pulmonary hypertension has not been studied in the gener

139 maturity, cyanotic congenital heart disease, pulmonary hypertension, home respiratory support, neurom

140 in lungs of mice exposed to hypoxia-induced pulmonary hypertension (HPH).

141 ions where inhaled NO is beneficial, such as pulmonary hypertension, hypoxemia, and cystic fibrosis.

142 d from the ASPIRE (Assessing the Spectrum of Pulmonary Hypertension Identified at a Referral Center)

143 d from the ASPIRE (Assessing the Spectrum of Pulmonary Hypertension Identified at a Referral Centre)

144 harge (grade III or IV aortic regurgitation, pulmonary hypertension) identified patients at high risk

145 erves lung growth and function, and prevents pulmonary hypertension in a rat model of chorioamnioniti

146 nversion of androgens to estrogen and blunts pulmonary hypertension in animals, but its efficacy in t

147 In vivo, high-dose Poly(I:C) reduced pulmonary hypertension in both rat models in proof-of-pr

148 rdenafil, currently used to treat paediatric pulmonary hypertension in children, could be repurposed

149 hophysiology, and management implications of pulmonary hypertension in patients with obstructive hype

150 to non-invasively monitor the progression of pulmonary hypertension in preclinical models and potenti

151 induced hemodynamic and vascular changes of pulmonary hypertension in rats (n=8) and elevated interl

152 cell infiltration, and regresses established pulmonary hypertension in rats.

153 Pulmonary hypertension in the setting of heart failure w

154 nd that antagonism of miR-29 would attenuate pulmonary hypertension in transgenic mouse models of Bmp

155 1 in transgenic mice worsens hypoxia-induced pulmonary hypertension, in association with impaired EC

156 r in women, with the exception of those with pulmonary hypertension, in whom, there was a significant

157 rstitial pneumonias are often complicated by pulmonary hypertension, increasing morbidity and mortali

158 s study sought to determine whether baseline pulmonary hypertension influences outcomes of transcathe

159 Pulmonary hypertension is a common hemodynamic complicat

160 Pulmonary hypertension is a fatal disease, however relia

161 Pulmonary hypertension is an established outcome predict

162 f the underlying disease, the development of pulmonary hypertension is associated with clinical deter

163 Management of adults with sickle-related pulmonary hypertension is based on anticoagulation for t

164 Exercise pulmonary hypertension is independently associated with

165 Given that pulmonary hypertension is strongly associated with envir

166 Progression of hypoxic pulmonary hypertension is thought to be due, in part, to

167 ally prevent against chronic hypoxia-induced pulmonary hypertension judged by right ventricular systo

168 lmonary and systemic vasculopathy, including pulmonary hypertension, leg ulcers, priapism, chronic ki

169 Severe ventricular dysfunction and/or pulmonary hypertension may not be amenable to corrective

170 ery pressure greater than 39 mm Hg predicted pulmonary hypertension (mean pulmonary artery pressure >

171 Pulmonary hypertension (mean pulmonary artery pressure,

172 %) met hemodynamic criteria for precapillary pulmonary hypertension (mean pulmonary artery pressure,

173 Patients with severe chronic thromboembolic pulmonary hypertension (n = 15) had higher EVLWPBW value

174 ntrol subjects (symptomatic patients without pulmonary hypertension, n=139).

175 cemia, septic shock, endotoxemia, persistent pulmonary hypertension, nitric oxide, extracorporeal mem

176 enable preclinical imaging of rat models of pulmonary hypertension on a Bruker 7 T scanner.

177 with incomplete recovery and persistence of pulmonary hypertension on the 24-mo control should be fu

178 f eight), pulmonary embolism (two of eight), pulmonary hypertension (one of eight), and lymphopenia (

179 r inhibition, has beneficial effects against pulmonary hypertension onset and progression.

180 t reveal significant differences in residual pulmonary hypertension or RV dysfunction.

181 ty for patients with advanced heart failure, pulmonary hypertension, or acute myocardial infarction a

182 0.01 and p = 0.04, respectively) and severe pulmonary hypertension (p = 0.014 and p = 0.05, respecti

183 rial pressures versus isolated postcapillary pulmonary hypertension (P<0.05).

184 nts may develop hepatic encephalopathy (HE), pulmonary hypertension (PaHT), or liver tumors, among ot

185 sodilators are unlikely to benefit group 2/3 pulmonary hypertension patients and may cause harm.

186 had the greatest power to differentiate the pulmonary hypertension patients from controls (AUC: 0.84

187 e to clarify the diagnosis and clustering of pulmonary hypertension patients into cohorts beyond the

188 y to reassess treatment appropriateness when pulmonary hypertension patients seek prescriptions from

189 In pulmonary hypertension patients, the asymptotic pressure

190 omplexity has not previously been studied in pulmonary hypertension patients.

191 s, and special patient populations including pulmonary hypertension, pediatrics, and pregnancy.

192 n/P-selectin axis on vascular remodeling and pulmonary hypertension (PH) after hypoxia remain unexplo

193 However, persistent pulmonary hypertension (PH) after PEA remains a major de

194 isk for bronchopulmonary dysplasia (BPD) and pulmonary hypertension (PH) after preterm birth.

195 The pathophysiology of pulmonary hypertension (PH) and heart failure (HF) inclu

196 es atrial arrhythmogenesis in a rat model of pulmonary hypertension (PH) and, if so, to define the un

197 Pulmonary hypertension (PH) associated with left heart d

198 Rationale: Pulmonary hypertension (PH) associated with neurofibroma

199 Americans develop chronic kidney disease and pulmonary hypertension (PH) at disproportionately high r

200 Although pulmonary hypertension (PH) contributes significantly to

201 Pulmonary hypertension (PH) due to left heart disease (L

202 Pulmonary hypertension (PH) exists when mean pulmonary a

203 articular microRNAs, in the manifestation of pulmonary hypertension (PH) has advanced considerably ov

204 ts with bronchopulmonary dysplasia (BPD) and pulmonary hypertension (PH) have accelerated lung aging

205 ection fraction (HFpEF) patients who develop pulmonary hypertension (PH) have an increased risk of de

206 bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension (PH) have increased morbidity and

207 Pulmonary hypertension (PH) in adults with sickle cell d

208 been evaluated as a therapeutic strategy for pulmonary hypertension (PH) in experimental models of PH

209 emodeling is associated with the severity of pulmonary hypertension (PH) in HF.

210 Pulmonary hypertension (PH) in neonates, infants, childr

211 , TGF-beta blockade can prevent experimental pulmonary hypertension (PH) in pre-clinical models.

212 Pulmonary hypertension (PH) is a common clinical conditi

213 Pulmonary hypertension (PH) is a debilitating disease ch

214 Pulmonary hypertension (PH) is a feature of a variety of

215 RATIONALE: Pediatric pulmonary hypertension (PH) is a heterogeneous condition

216 Rationale: Pulmonary hypertension (PH) is a life-threatening cardio

217 Pulmonary hypertension (PH) is an independent risk facto

218 Bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension (PH) is an infantile lung disease

219 Pulmonary hypertension (PH) is associated with increased

220 Pulmonary hypertension (PH) is characterized by pulmonar

221 Chronic pulmonary hypertension (PH) is characterized by the accu

222 Severe pulmonary hypertension (PH) is considered to negatively

223 Pulmonary hypertension (PH) is diagnosed by a mean pulmo

224 Pulmonary hypertension (PH) is frequently reported in pa

225 Pulmonary hypertension (PH) is frequently reported in pa

226 Pulmonary hypertension (PH) is increasingly recognized a

227 rase-5 inhibitors (PDE5i) for groups 2 and 3 pulmonary hypertension (PH) is rising nationally, despit

228 e role of right ventricular (RV) fibrosis in pulmonary hypertension (PH) remains a subject of ongoing

229 ated with survival in this group and whether pulmonary hypertension (PH) reversal can influence LDL-C

230 Hepatitis C virus (HCV) may increase pulmonary hypertension (PH) risk among people living wit

231 The presence of pulmonary hypertension (PH) significantly worsens outcom

232 An emerging metabolic theory of pulmonary hypertension (PH) suggests that cellular and m

233 first nongenetically driven murine model of pulmonary hypertension (PH) that generates robust and di

234 associations by CHD severity and presence of pulmonary hypertension (PH) were examined.

235 nd to be of clinical value for assessment of pulmonary hypertension (PH) with studies to date exclusi

236 itochondrial metabolism, have been linked to pulmonary hypertension (PH), a deadly vascular disease w

237 Pulmonary hypertension (PH), a hypoxia-driven vascular d

238 Failure of this transition leads to pulmonary hypertension (PH), a major cause of newborn mo

239 were measured in group 1 PAH, group 2 and 3 pulmonary hypertension (PH), and in patients with severe

240 ells (PAECs) contributes to the pathology of pulmonary hypertension (PH), but changes in substrate up

241 lar septal flattening, frequently present in pulmonary hypertension (PH), can be quantified using ecc

242 In pulmonary hypertension (PH), microRNA-210 (miR-210) in p

243 ons between genes and selected phenotypes of pulmonary hypertension (PH), we used the Bayesian rare-v

244 e examined to determine associations between pulmonary hypertension (PH), with or without elevated le

245 remodeling of the pulmonary vasculature and pulmonary hypertension (PH).

246 n is an important determinant of outcomes in pulmonary hypertension (PH).

247 tric cardiac MRI models for the diagnosis of pulmonary hypertension (PH).

248 ry arterial hypertension and to experimental pulmonary hypertension (PH).

249 ft heart disease is the most common cause of pulmonary hypertension (PH).

250 ylcholinesterase inhibition, in experimental pulmonary hypertension (PH).

251 pulmonary macrophages in the pathogenesis of pulmonary hypertension (PH).

252 RA size is prognostic of adverse outcomes in pulmonary hypertension (PH).

253 scular wall cells, including fibroblasts, in pulmonary hypertension (PH).

254 ay a critical role in the pathophysiology of pulmonary hypertension (PH).

255 ents one of the major pathologic features of pulmonary hypertension (PH).

256 enitor marker CD117 promote severe occlusive pulmonary hypertension (PH).

257 le cells (PASMCs) plays an important role in pulmonary hypertension (PH).

258 n for its propensity to improve experimental pulmonary hypertension (PH).

259 RV) hypertrophy and fibrosis associated with pulmonary hypertension (PH).

260 dence that current thresholds for diagnosing pulmonary hypertension (PHT) underestimate the prognosti

261 g patients with CDH and its association with pulmonary hypertension (pHTN) and mortality.

262 tracardiac repair, systemic right ventricle, pulmonary hypertension, pulmonary regurgitation, pulmona

263 er or cancer therapy-associated systemic and pulmonary hypertension, QT prolongation, arrhythmias, pe

264 0 risk score calculator or a modified French Pulmonary Hypertension Registry approach, improved risk

265 ced, or heritable PAH enrolled in the French pulmonary hypertension registry between 2006 and 2016 wh

266 ypertension Identified at a Referral Centre) pulmonary hypertension registry.

267 , peripheral arterial disease, hypertension, pulmonary hypertension, renal or liver disease, New York

268 95% of patients with or without preoperative pulmonary hypertension, respectively, were asymptomatic

269 ronary artery disease, mitral regurgitation, pulmonary hypertension, right ventricular dilation and d

270 characterize a large sarcoidosis-associated pulmonary hypertension (SAPH) cohort to better understan

271 The remainder have postcapillary pulmonary hypertension secondary to left ventricular dys

272 ow RV-pulmonary arterial coupling relates to pulmonary hypertension severity and onset of RV failure

273 e severity of LV dysfunction, LV dilatation, pulmonary hypertension, severity of tricuspid regurgitat

274 tal disorder causing respiratory failure and pulmonary hypertension shortly after birth.

275 Our findings suggest IUGR-induced pulmonary hypertension should be further investigated an

276 ats were more susceptible to hypoxia-induced pulmonary hypertension than wild-type rats.

277 Each of these two phases results in severe pulmonary hypertension that directly leads to right vent

278 ertension and identifies a level of residual pulmonary hypertension that may guide the long-term mana

279 kers was assessed in the RV of patients with pulmonary hypertension, the murine pulmonary artery band

280 In pulmonary hypertension, the right ventricle adapts to th

281 In pulmonary hypertension, the status of the right ventricl

282 ry edema in PVOD, if treated by conventional pulmonary hypertension therapy.

283 ubjects enrolled in the PVDOMICS (Redefining Pulmonary Hypertension through Pulmonary Vascular Diseas

284 mportant mediator that drives RV fibrosis in pulmonary hypertension through the expansion of PDGFRalp

285 PH-LHD patients from isolated postcapillary pulmonary hypertension to Cpc-PH, which is characterized

286 clinical conditions ranging from portal and pulmonary hypertension to pulmonary, cardiac and renal f

287 ease in patients with chronic thromboembolic pulmonary hypertension undergoing PEA to predict postope

288 ation, 63 years +/- 17) with newly diagnosed pulmonary hypertension underwent cardiac magnetic resona

289 diseases (CVDs), including atherosclerosis, pulmonary hypertension, valvular disease, and fibroelast

290 In pulmonary hypertension vascular remodeling leads to narr

291 evated E/e' ratio was 53%, and prevalence of pulmonary hypertension was 31%.

292 Exercise pulmonary hypertension was ascertained using minute-by-m

293 Pulmonary hypertension was common in obstructive hypertr

294 mutants demonstrated that the development of pulmonary hypertension was dependent on HIF-2alpha but n

295 Interestingly, pulmonary hypertension was present in 13 patients at bas

296 vious mouse model of Pneumocystis-associated pulmonary hypertension, we found that vascular remodelin

297 ic dysfunction, left atrial enlargement, and pulmonary hypertension were common in PARAGON-HF.

298 udy, 20 patients with chronic thromboembolic pulmonary hypertension were examined at 1.5 T with a dyn

299 fractional area change (P < 0.001), but not pulmonary hypertension, were independently associated wi

300 Pulmonary hypertension worsens prognosis in patients wit